Lymphedema — Swelling Caused by Fluid Build-Up

Lymphedema manifests when the body's lymphatic drainage apparatus is anatomically disrupted or mechanically overloaded, preventing fluid from returning to the venous system. As interstitial fluid accumulates, it triggers localised tissue inflammation, adipocyte hypertrophy, and progressive connective tissue fibrosis within the subcutaneous layer.

In cancer populations, secondary lymphedema most commonly affects the limbs, although it can also develop in the chest, breast, head, neck, or external genitalia depending on the site of medical intervention. Without management, the affected area may experience progressive tissue induration, skin thickening, and elevated vulnerability to recurrent secondary bacterial infections such as cellulitis.

Lymphedema significantly impacts long-term quality of life, physical comfort, and psychological well-being following successful cancer treatment. If left unchecked, chronic swelling can restrict joint mobility, impair fine motor function, and cause continuous discomfort. Furthermore, stagnant lymphatic fluid provides an ideal environment for rapidly spreading skin infections. Proactive surveillance enables early conservative management before irreversible tissue fibrosis occurs, ensuring individuals retain active and independent lives.

Diagnosis relies predominantly on clinical history and objective limb measurements, including circumferential tape measurements, water displacement volumetry, or perometry. Bioimpedance spectroscopy (BIS) is increasingly utilised to detect microscopic subclinical fluid changes before visible swelling appears. When functional imaging is required to map damaged channels, indocyanine green (ICG) lymphography or radionuclide lymphoscintigraphy provides real-time visualisation of lymphatic flow.

Lymphedema is most widely recognised as a secondary complication of breast cancer management following axillary node dissection or regional radiotherapy. However, it also occurs frequently in gynaecological malignancies—such as cervical, vulval, and endometrial cancers—and urological cancers, notably penile, testicular, and prostate cancers. It also affects patients treated for lower-extremity cutaneous melanoma, as well as individuals undergoing intensive therapy for advanced head and neck cancers.

Managing lymphedema focuses on decongestive measures rather than pharmacological cures. The standard of care is Complex Decongestive Therapy (CDT), which integrates manual lymphatic drainage, multi-layer compression bandaging, specialised exercise programmes, and diligent skin hygiene. For refractory cases, surgical options such as lymphovenous bypass or vascularised lymph node transfer may be evaluated in specialised centres to restore local drainage pathways.